Immunovia raised ~ 400m SEK to Further Accelerate the Market Introduction of the First Test for Early Detection of Pancreatic Cancer, the IMMray[™] PanCan-d
On June 4[th], Immunovia announced a Directed Share Issue raising ~400 MSEK in capital, resulting in one of the largest fundraising for a non-US based diagnostics company. Proceeds from this Directed Share Issue will be used for the commercialization activities associated with the launch of IMMray[™ ]PanCan-d. These activities include securing additional high caliber talent for the company’s sales, marketing and customer support teams. Additionally, funds will be used to increase Immunovia’s activities for reimbursement. LUND, SWEDEN – Immunovia AB (publ) (“Immunovia”) today provides